Inflammation in chronic venous ulcers

Phlebology

Volumn 28, Issue 1_suppl, 2013, Pages 61-67

  Raffetto, J D ^a,b  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

collagen; cytokines; extracellular matrix; growth factors; Inflammation; leukocytes; macrophages; matrix metalloproteinases; venous ulcer; wound fluid

Indexed keywords

CYTOKINE; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12P40; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; PROGELATINASE A; PROGELATINASE B; PROTEIN PRECURSOR; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VASCULOTROPIN; AUTACOID; SIGNAL PEPTIDE;

AGE DISTRIBUTION; CHRONIC VEIN INSUFFICIENCY; CHRONIC VENOUS ULCER; COLLAGEN METABOLISM; CYTOKINE RELEASE; ENZYME ACTIVITY; HEALTH CARE COST; HEREDITY; HUMAN; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY CELL; LEG ULCER; MICROCIRCULATION; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SEX DIFFERENCE; VEIN DISEASE; WOUND HEALING IMPAIRMENT; CHRONIC DISEASE; ECONOMICS; METABOLISM; PATHOLOGY; PROGNOSIS; RISK FACTOR; SKIN; VARICOSIS; WOUND HEALING;

CHRONIC DISEASE; CYTOKINES; HEALTH CARE COSTS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MATRIX METALLOPROTEINASES; PROGNOSIS; RISK FACTORS; SKIN; VARICOSE ULCER; WOUND HEALING;

EID: 84883199140     PISSN: 02683555     EISSN: 14333031     Source Type: Journal    
DOI: 10.1177/0268355513476844     Document Type: Review

References (21)

1. Bergan JJ, Schmid-Schonbein GW, Smith PD. Chronic venous disease. N Engl J Med 2006; 355: 488–98
2. McGuckin M, Waterman R, Brooks J. Validation of venous leg ulcer guidelines in the United States and United Kingdom. Am J Surg 2002; 183: 132–7
3. Raffetto JD. Dermal pathology, cellular biology, and inflammation in chronic venous disease Thromb Res 2009; 123(Suppl. 4): S66–71
4. Liu YC, Margolis DJ, Isseroff RR. Does inflammation have a role in the pathogenesis of venous ulcers?: a critical review of the evidence. J Invest Dermatol 2011; 131: 818–827
5. Scott HJ, Coleridge Smith PD, Scurr JH. Histological study of white blood cells and their association with lipodermatosclerosis and venous ulceration. Br J Surg 1991; 78: 210–1
6. Wilkinson LS, Bunker C, Edwards JC. Leukocytes: their role in the etiopathogensis of skin damage in venous disease. J Vasc Surg 1993; 17: 669–75
7. Weyl A, Vanscheidt W, Weiss JM. Expression of the adhesion molecules ICAM-1, VCAM-1, and E-selectins and their ligands VLA-4 and LFA-1 in chronic venous leg ulcers. J Am Acad Dermatol 1996; 34: 418–23
8. Saharay M, Shields DA, Porter JB. Leukocyte activity in the microcirculation of the leg in patients with chronic venous disease. J Vasc Surg 1997; 26: 265–73
9. Pappas PJ, DeFouw DO, Venezio LM. Morphometry assessment of the dermal microcirculation in patients with chronic venous insufficiency. J Vasc Surg 1997; 26: 784–95
10. Trengove NJ, Stacey MC, MacAuley S. Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors. Wound Repair Regen 1999; 7: 442–52
11. Trengove NJ, Bielefeldt-Ohmann H, Stacey MC. Myogenic activity and cytokine levels in non-healing and healing chronic leg ulcers. Wound Repair Regen 2000; 8: 13–25
12. Tian YW, Stacey MC. Cytokines and growth factors in keratinocytes and sweat glands in chronic venous leg ulcers. An immunohistochemical study. Wound Repair Regen 2003; 11: 316–25
13. Beidler SK, Douillet CD, Berndt DF. Inflammatory cytokine levels in chronic venous insufficiency ulcer tissue before and after compression therapy. J Vasc Surg 2009; 49: 1013–20
14. Gohel MS, Windhaber RA, Tarlton JF. The relationship between cytokine concentrations and wound healing in chronic venous ulceration. J Vasc Surg 2008; 48: 1272–7
15. Wysocki AB, Staiano-Coico L, Grinnell F. Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. J Invest Dermatol 1993; 101: 64–8
16. Weckroth M, Vaheri A, Lauharanta J. Matrix metalloproteinases, gelatinase and collagenase in chronic leg ulcers. J Invest Dermatol 1996; 106: 1119–24
17. Herouy Y, May AE, Pornschlegel G. Lipodermatosclerosis is characterized by elevated expression and activation of matrix metalloproteinases. Implications for venous ulcer formation. J Invest Dermatol 1998; 111: 822–7
18. Herouy Y, Trefzer D, Hellstern MO. Plasminogen activation in venous leg ulcers. Br J Dermatol 2000; 143: 930–6
19. Norgauer J, Hildenbrand T, Idzko M. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 2002; 147: 1180–6
20. Mwaura B, Mahendran B, Hynes N. The impact of differential expression of extracellular matrix metalloproteinase inducer, matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2 and PDGF-AA on the chronicity of venous leg ulcers. Eur J Vasc Endovasc Surg 2006; 31: 306–10
21. Meyer FJ, Burnand KG, Abisi S. Effect of collagen turnover and matrix metalloproteinase activity on healing of venous leg ulcers. Br J Surg 2008; 95: 319–25